
ASX:TTX
#anchoredbyscience
Tetratherix™

IMPORTANT INFORMATION & DISCLAIMER

USE OF THIS DOCUMENT
You must read the following notices before reading or making any use of this document or any information contained in this document. By continuing to read, use or otherwise act on this document, you agree to be bound by the following terms and conditions, including any modifications to them, and make or give the acknowledgements, representations or warranties (as applicable). This presentation is provided for information purposes only. The information in this presentation is in a summary form, does not purport to be complete and is not intended to be relied upon as advice to investors or other persons. The information contained in this presentation was prepared by Tetratherix Pty Limited ACN 607 771 077 (Tetratherix) as of its date, and remains subject to change without notice. This presentation has been provided to you solely for the purpose of giving you background information about Tetratherix.

NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES
This document is not to be distributed or released in the United States.

DISTRIBUTION OUTSIDE AUSTRALIA
The distribution of this presentation to persons or in jurisdictions outside Australia may be restricted by law and any person into whose possession this document comes should seek advice on and observe those restrictions. Any failure to comply with such restrictions may violate applicable securities law.

FORWARD-LOOKING STATEMENTS
This presentation may include forward looking statements. Such statements can generally be identified by the use of words such as 'may', 'will', 'expect', 'intend', 'plan', 'estimate', 'anticipate', 'believe', 'continue', 'objectives', 'outlook', 'guidance', 'forecast' and similar expressions. Indications of plans, strategies, management objectives, revenue and financial performance are also forward-looking statements. Such statements are not guarantees of future performance, and involve known and unknown risks, uncertainties, significant items of subjective judgement, assumptions (including in relation to future events that may or may not eventuate), contingencies and other factors, many of which are outside the control of Tetratherix. No independent third party has reviewed the reasonableness of any such statements or assumptions. No representation is made or will be made that any forward-looking statements will be achieved or will prove to be correct. Actual results, performance, operations or achievements may vary materially from any forward-looking statements. Circumstances may change and the contents of this presentation may become outdated as a result. Readers are cautioned not to place undue reliance on forward looking statements. Except as required by law, Tetratherix assumes no obligation to release updates or revisions to forward looking statements to reflect any changes. You should form your own views as to these matters and any assumptions on which such statements are based and not place reliance on such statements. No representation or warranty, expressed or implied, is made as to the accuracy, reliability, adequacy or completeness of the information contained in this presentation. To the maximum extent permitted by law, Tetratherix excludes and disclaims all liability, including (without limitation) any liability for fraud or negligence, for any expenses, losses, damages or costs incurred either as a result of the information in this presentation being inaccurate or incomplete in any way for any reason, or otherwise arising in connection with this presentation.

PAST PERFORMANCE AND RISKS
Past performance information given in this presentation is given for illustrative purposes only and should not be relied upon as (and is not) an indication of future performance. An investment in Tetratherix is subject to known and unknown risks, some of which are beyond the control of Tetratherix, including factors and risks specific to the industry in which it operates as well as general economic conditions, prevailing exchange rates and interest rates and conditions in the financial markets. Tetratherix does not guarantee any particular rate of return on its performance nor does it guarantee any particular tax treatment. Prospective investors should make their own enquiries and investigations regarding all information in this presentation, including the assumptions, uncertainties and contingencies which may affect future operations and the impact that different future outcomes may have on Tetratherix.

NO OFFER, INVITATION OR ADVICE
This presentation is not, and is not intended to constitute, financial advice, or an offer or an invitation, solicitation or recommendation to acquire or sell Tetratherix shares or any other financial products in any jurisdiction and is not a prospectus, product disclosure statement, disclosure document or other offering document under Australian law or any other law. This presentation does not form the basis of any contract or commitment to sell or apply for securities in Tetratherix or any of its subsidiaries. It is for information purposes only. Tetratherix does not warrant or represent that the information in this presentation is free from errors, omissions or misrepresentations or is suitable for your intended use. The information contained in this presentation has been prepared without taking account of any person's investment objectives, financial situation or particular needs and nothing contained in this presentation constitutes investment, legal, tax or other advice. The information provided in this presentation may not be suitable for your specific needs and should not be relied upon by you in substitution of you obtaining independent advice. Subject to any terms implied by law and which cannot be excluded, Tetratherix accepts no responsibility for any loss, damage, cost or expense (whether direct, or indirect, consequential, exceptional or special damages including but not limited to loss of revenue, profits, time, goodwill, data, anticipated savings, opportunity, business reputation, future reputation, production or profit, any delay costs, economic loss or damage) incurred by you as a result of any error, omission or misrepresentation in this presentation.

UNAUDITED INFORMATION
All forward-looking figures and proforma statements in this presentation are unaudited. Certain figures may be subject to rounding differences. All market share information in this presentation is based on management estimates having regard to internally available information unless otherwise stated.

PRESENTATION OF INFORMATION
All currency amounts in this presentation are in Australian dollars unless otherwise stated.

PRESENTING

Will Knox

CEO

Will comes from a long history of medical and biological technology development. Prior to Tetratherix, Will has worked for small and large businesses in Australia and offshore such as Cochlear, Medtronic and LifeHealthcare. Will has also established his own company in regenerative medicine that was acquired in 2017 by Australian private equity. Combining both the clinical and commercial worlds, Will brings a unique and well respected combination of skillsets to our business.

Dr Ali Fathi

FOUNDER & CTO

Ali is a world-renowned researcher and inventor of Tetramatrix and has continued the development of the technology using his technical and entrepreneurial vision. Ali is a globally respected chemical engineer and is one of Australia's most published young researchers. Using his unique approach to engineering science-based solutions for the real world, Ali has created a technology that has been deliberately considered from start to finish.

PRESENTING

Cherie Beach

CFO

Cherie is the epitome of a strategic CFO and brings many years of experience within healthcare and medical technology. Cherie was most recently a senior finance leader at Cochlear and Johnson&Johnson, and has a long history of strategic financial stewardship in our industry. Cherie has an unparalleled combination of leading global financial process with fast-growing innovative thinking - a combination that allows us to grow rapidly while ensuring commercial stability & reliability.

Terence Abrams

FOUNDER & COO

Terence (Tez) is an extremely experienced chemical engineer who has over a decade of experience in bespoke compounding, polymer production & infrastructure design for complex biomaterials. Tez is the engine that drives the unique differentiation behind our advanced manufacturing. Adopting critical thinking and first principles, Tez is a pragmatic problem solver who combines chemistry, quality systems and commercial objectives - a skillset that is standalone in our industry.

The executive leadership team are supported by a deep bench of scientific & commercial advisors who are highly regarded leaders in their respective fields

Tetratherix™

Tetramatrix™ platform technology is the world's first biostealth fluid matrix

A fully synthetic biomaterial used to optimise precision medicine. Compatible with minimally invasive administration techniques, with no foreign body reaction induced.

Intelligent

The material is an injectable fluid to avoid causing damage to the body during its application. Upon injection, triggered by physiological temperature, a 3D matrix is formed that physically integrates and adheres to the target tissue.

Modular

A biomaterial platform built with unique polymer programming akin to "medical Lego® " to form implantable products to solve a wide range of clinical problems.

Biomimetic

The matrix has similar water content and mechanical properties to natural tissue, and therefore is impervious to the body, bridging healthy and injured tissues, helping heal injuries or physically manipulating the body during surgical interventions.

Safe

Due to the unique polymer programming of the material, once the matrix serves its purpose, the material gradually and safely bioresorbs in the body with no impact locally or systemically.

Tetramatrix™



Supported by complete IP coverage

Patent stack with 36 granted patents from 9 families of patent, extending to 2040 & beyond and fully owned by Tetratherix

Tetratherix™

Why does the world need Tetratherix?

The evolving dynamics of the global healthcare system is demanding innovative and cost-effective biomaterials

Trends in healthcare delivery	How does Tetramatrix address the problem?

Rising patient expectations

Patients are demanding increasingly higher quality of care, with a particular focus on **reducing recovery times** and **lowering risk of complications** (e.g. infection, blood loss, pain) - which is also a driver of increasing healthcare costs for patients and payers.

Minimally invasive delivery
Water-based solution injected through fine gauge needle

Safe, biocompatible and bioresorbable
No foreign body reaction upon application

Need for cost-effective, decentralised care

Increasing global healthcare spending and demand for healthcare services is necessitating investment in **cost-effective tools and treatments**, including those that can be **delivered outside a traditional hospital setting**, to minimise burden on the healthcare system

Low cost, scalable production
Non-labour intensive, low cost and readily available materials

Seamlessly integrated into existing workflows
Delivered via needle with no additional equipment required

Tetratherix™

Company History

Tetramatrix Invented

2011

2015

Tetratherix founded in Sydney Australia

Tetratherix™

2016

First patent family and safety results completed

2017

Established production facility in Alexandria and ISO:13485 certification

2018

First Skeletal Reconstruction trial completed

2019

Dermal repair project commenced

2020

Series A financing completed and second Skeletal Reconstruction trial commences

2021

Corporate structure established with CEO hire and commercial scale production established

2022

Dental commercial partnership commences and new polymer configuration Invented (used in Spacing program)

2023

FDA engagement & Orthopaedic commercial partnership commences

2024

Dermal clinical trial commenced Spacing program commenced with KOLs in AU & US

2025

Henry Schein Partnership Master Agreement executed and BioOptix project commenced

Tetratherix™

Derived products from the Tetramatrix platform technology span 3 large franchises and significant near-term commercial opportunities

Bone Regeneration

Flowable bone graft extender for orthopaedic applications



Bone graft extender for dental surgeries



Tissue Spacing

Spacer during cataract surgeries



Prostate Spacer for radiation therapy



Tissue Healing

Intraoperative solution to reduce scar formation after surgeries







Same core technology, same material and interchangeable dataset

95%

FDA

Tetratherix™

Different clinical needs. Different market segments. Single Tetramatrix™ platform technology.



Think of us like a SaaS business...

The Tetramatrix biomaterial is our **core 'platform' technology**. We have completed the foundational safety, efficacy and manufacturing work which is transferable across different clinical applications of the platform.

We **license the IP** in a specific field to a leader in the segment. These partners complete the "final 20%" to turn the application into a clinical product. We then manufacture the product and supply at attractive unit economics to our industry leading partners who distribute it though their sales channels.

We enjoy periodic milestone payments as well as a steady flow of income from product supply - a dual revenue source brings the best of both worlds.



Tetratherix™

A capital light model with compounding revenue

While we build our own production and R&D infrastructure, we avoid committing capital on establishing multiple sales & distribution networks by utilising the capabilities of our partners' established teams.

Importantly, we operate in unison with our partners. Our high margin revenue compounds over time by adding new partnerships and launching new products.

Similar to a 'build-to-buy' model, we partner differently to, and at earlier stages than, traditional medtech companies. Therefore, our return profile is different and not built on expectations of an eventual acquisition.

"Tetratherix is SaaS software platform thinking applied to the vast opportunity for smart medicines. I'm excited about the many applications that can be delivered over time and the impact they will have to millions of people."

Rod Drury
Xero Founder & Tetratherix Investor



Tetratherix™

Not simply a science experiment. Tetramatrix™ provides real world economics.

	Bone Regeneration	Tissue Spacing	Tissue Healing
TAM	US$3.4bn	US$1.3bn	US$2.1bn
Payer	Patient out-of-pocket	Reimbursed (US)	Patient out-of-pocket
Expected GM[1] for Partner	70-80%	~80-90%	~70-80%
Expected GM for TTX	60-70%	~75-85%	~60-70%

We verify the final end user pricing and the gross margin targets for our strategic partners before progressing

1. Weighted Blended Gross Margin

Tetratherix™

Advance manufacturing and operations

We have established advanced manufacturing in Sydney. To meet growing demand, a new facility is planned to be commissioned in 2026, with a modular design to allow us to quickly scale as needed.

Our manufacturing process is:

Highly Scalable with supply chain security

- Our manufacturing process is design in a 'POD' framework whereby every POD can operate independently
- The POD has a foot print of 200 sqm, and can be replicated multiple times without our facility floorspace
- Allows multiple X increases in the production capacity in a fast and controlled manner

De-risked

- We have previously increased our production yield per batch from laboratory scale (10 g per batch) to a commercial scale (1.2kg) through multiple cycles of process optimisation and scale up
- The production process is not labour-intensive and requires only off-the-shelf equipment
- All raw materials are catalogue products and easily accessible from multiple suppliers, de-risking any supply chain risk
- A new, larger site in Alexandria, Sydney has been identified with negotiations ongoing for a long-term lease

Externally Validated

- Production blueprint validated for further upscale with an external European CMO
- Our process has been governed by an EN ISO13485 certified quality management system since 2017 successfully completing three re-certification audits

Manufacturing POD


Tegenix

Tegenix | Bone Regeneration – Dental

Tetratherix™

A universal enabling solution to simplify complex oral & dental procedures

An innovative carrier designed to be mixed with a broad array of bone graft materials (BGMs) for dental and oral applications.



Partners

THE UNIVERSITY OF SYDNEY · NYU · THE UNIVERSITY OF WESTERN AUSTRALIA

Key features

Modular and Flexible

1 A carrier system for any and every type of graft to form mouldable and shapable composites for easy and gentle delivery, which preserves the integrity of the host tissue for faster healing.

Simplifying Complex Procedures

2 Adhesive plug that negates the need for primary closure and/or membranes which reduces the cost, and simplifies surgical procedures, including guided bone regeneration.

Supports Natural Healing

3 The matrix maintains the graft in 3D geometry to allow cellular ingrowth and integration within the composite. The biocompatible nature of the hydrogel works synergistically with any graft, supporting natural healing.

Tegenix | Market Seeding in 2026 with a Market Leader in Dentistry

Pilot Clinical Trials (2X)	✓	FDA Pathway Defined	✓	FDA Clearance	H1 CY2026
Master Partnership Agreement	✓	Manufacturing Ready	✓	Market Seeding	H2 CY2026




Tutelix

Tutelix™ | Tissue Spacing - Oncology

Tetratherix™

Safe & easy to use solution for more effective & simpler spacing in radiation oncology

Tutelix™ is intended for use as a spacer to reduce side effects to surrounding tissue during radiation therapy to treat prostate cancer. It is easily injected and is gradually resorbed by the body and excreted over time (12 weeks) without harm to any internal organs



Injection to the space between prostate/ rectum

Space generation to reduce side effects to rectum during radiation

Partners

ICON GROUP | The University Of Queensland AUSTRALIA

Key features

Procedure Optionality

1 A water-based solution makes the product amenable to single injection after hydrodissection OR as multiple gradual injections, two commonly used techniques.

Simple to adjust (+/- volume)

2 Activated organically by body temperature, the solution transitions into a hydrogel. The hydrogel is smooth, flowable and can be immediately reversed with cold-saline. The hydrogel breaks down to non-toxic components and bioresorbs within 3 to 6 months completely.

Visible to physicians under both CT-scan and ultrasound

3 In contrast to incumbent products, the product is visible under Computed Tomography without enhancement which allows for a safer, simpler, more accurate and cost-effective outcome when delivering radiotherapy.

Utelix | AU/US Clinical Trial in 2026

Tetratherix™

HREC Approval	✓	Large Animal Studies	✓	Quality and Supply Agreement	In CY2027
License Agreement + JV	✓	AU/ US Clinical Trial	In 2026	FDA Clearance	In CY2028




Optelex

Optelex™ | Tissue Spacing - Ophthalmology

Tetratherix™

Novel Synthetic reversible OVD for safe & simple application

Optelex is a fully synthetic solution that maintains the volume and shape of the eye during surgery that can be removed via a simple saline wash. The product reduces the reliance of partners on animal derived materials. Most importantly, by reversing the gelation of the product by cold saline dissolution, the risks associated with inflammation from product residues - a common risk for all current products- is fully mitigated.



Partners

MANHATTAN EYE Northwell Health

Key features

1 Synthetic - Not animal-derived

The product is fully synthetic and there is no animal derived component used in the product, which provides supply chain security to the partner

2 Low cost and scaled manufacturing

Low cost of goods, scalable production and controlled sterility and endotoxins provide commercially attractive unit economics

3 Easy to remove & reduces known side effects

The product's instant dissolution by lowering the temperature of the site via cold saline, allows easy and fast removal of the product after the completion of the surgery.

Optelex™ | First I US Clinical Trial in 2027

Master Partnership Agreement	✓	Supply and License Agreement	H2 CY2025	FDA Correspondence	Mid CY2025
Invention and patent submission	✓	Clinical Trial	CY2027		




TetraDerm

TetraDerm | Tissue Healing

The world's first intraoperative scar prevention solution

TetraDerm is the only flowable matrix that can be used intraoperatively to provide an internal cushioning effect to physically decrease mechanical tension and dead space, therefore reducing scar formation after any surgery, such as surgical reconstruction, arthroplasty and caesarean procedures



Partners

THE UNIVERSITY OF SYDNEY
ANZAC Research Institute

Key features

1 Easy to apply and able to be used intraoperatively

A flowable dermal matrix that forms a uniform hydrogel within dermal layers without the need for any external stimuli, such as light or chemical reaction- gelation is triggered by physiological temperature.

2 Superior efficacy in tissue remodelling and wound closure

The mimetic of the hydrogel allows biological integration of the hydrogel within the host tissue and provides a physical scaffold for cellular regeneration and skin remodelling.

3 Decreases myofibroblast activity and scar formation

Mechanical tension is the driving force known to increase myofibroblast activity and consequently scar formation. The matrix provides an internal cushioning effect to reduce mechanical tension and dead space, thus preventing scar formation.

TetraDerm | Ongoing Clinical Data Readout

Tetratherix™

Technical Validation	✓	FDA Correspondence	✓	Customer Need Identified	✓
Clinical Trial	✓	FDA Clearance	1H CY2029	Manufacturing Ready	✓



Near Term Milestones

Tetratherix™

Relentless execution with Regular newsflow in first 12 months post-listing

Bone Regeneration

Tissue Spacing

Tissue Healing

DENTAL	FDA Studies on Track	**Henry Schein Supply and Licensing agreement execution**	Data Read-out from the FDA study	FDA Submission		**FDA Clearance**
ORTHOPAEDIC	FDA Studies on Track	Master Partnership Agreement execution	**Supply and Licensing agreement execution**	FDA Submission		**FDA Clearance**
ONCOLOGY	FDA Pre-submission/ Regulatory Pathway Defined	**Tutelix First In Human Cohort 1 (n=3)**	Quality Agreement execution	US/AU Capital Raise	**Tutelix Primary End Point for Cohort 2 (n=15 to 30)**	**US Clinical Trial Initiation**
OPHTHALMIC	**BioOptix Licensing Agreement**	Strategic global partnership	US/ AU Capital Raise	Preclinical Data Read-out		**FDA Pre-submission/ Regulatory Pathway**
SURGICAL SITE MGMT	Cohort 2 Commenced	**Year 1 Follow up for Cohort 1 results published**	Primary End-point Cohort 2	**FDA Pre-submission/ Regulatory Pathway**		TetraDerm Cohort 3 Initiation (major surgeries)

Roadshow **FY2026** **FY2027**

Strategic Licence Agreement signed with BioOptix Inc.

Tetratherix and the New York-based ophthalmic company will develop and commercialise a novel ophthalmic viscoelastic device (OVD), built upon Tetratherix' polymer platform.

- Global OVD market is estimated to have a **total addressable value of USD ~$700 million p.a.**, with minimal innovation in recent decades,
- Tetratherix **invented two new polymer formulations** (PH2O and PH2NO) to address the shortcomings in OVD applications. A new **Australian Provisional Patent** has been submitted. The forming products are flowable and forms **transparent gel** as opposed to white/opaque structure.
- Partnership model enables **rapid commercial entry into targeted markets** & capital-light model for Tetratherix, with BioOptix responsible for funding clinical & regulatory activities through a 5+5+5 years agreement.
- Tetratherix will provide its **platform technology, products, services, technical support, and testing in return for a licence fee during the development phase**
- Tetratherix will **continue to manufacture the products at its Australian facilities** during the commercialisation phase with **minimum purchase volumes agreed**, operating under its ISO13485 certified quality management system
- **BioOptix will manage capital raising for the venture** and engage with leading VC firms in the US as well as strategic partners